Immune checkpoint inhibitor combinations—current and emerging strategies

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

(2022) Somayeh Vafaei et al.   Cancer Cell International

A Randomized Ph2 Study of MEDI0680 in Combination With Durvalumab vs. Nivolumab Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

(2022) Martin H. Voss et al.   CLINICAL CANCER RESEARCH

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

(2022) Nazli Dizman et al.   NATURE MEDICINE

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

(2022) Yuchen Wang et al.   Journal of Hematology & Oncology

ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC).

(2022) Melissa Lynne Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 as a biomarker of response to immune-checkpoint inhibitors

(2021) Deborah Blythe Doroshow et al.   Nature Reviews Clinical Oncology

Development of Immunotherapy Combination Strategies in Cancer

(2021) Timothy A. Yap et al.   Cancer Discovery

Revisiting the PD-1 pathway

(2020) Nikolaos Patsoukis et al.   Science Advances

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

(2019) Y Fradet et al.   ANNALS OF ONCOLOGY